“…In addition to these classifications, GCs can be characterised on the molecular level [ 11 ]. Research has reported mutations in KRAS , APC , ARID1A , PIK3CA , ERBB3 , HLA-B , SMAD4 , STK11 , PTEN , and BMPR1A , amongst others, with the most frequent reports of mutations in CDH1 and TP53 [ 11 , 12 , 13 , 14 , 15 ]. The TME also plays a role in tumour progression, as it has been shown that a high amount of tumour stroma is associated with worse five-year survival in GC [ 16 ].…”